*** LIVE ***

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it?

“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular.

Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population.

Southern California – based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population.

First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding.


Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.


Sign up today!


DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.